[HTML][HTML] The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors,
with limited progress made in the area of myeloid malignancies. The low mutational burden …
with limited progress made in the area of myeloid malignancies. The low mutational burden …
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
EM Cherry, D Abbott, M Amaya, C McMahon… - Blood …, 2021 - ashpublications.org
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly …
DA Pollyea, A Winters, C McMahon… - Bone marrow …, 2022 - nature.com
The combination of venetoclax (ven) and azacitidine (aza) has resulted in high response
rates in the upfront treatment of AML in patients age> 75 and patients unfit for intensive …
rates in the upfront treatment of AML in patients age> 75 and patients unfit for intensive …
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment‐related mortality
A Maiti, W Qiao, K Sasaki, F Ravandi… - American journal of …, 2021 - Wiley Online Library
Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …
Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies
Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.
Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …
transformed the therapeutic landscape for patients diagnosed with this disease. By …
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
NG Daver, S Iqbal, C Renard, RJ Chan… - Journal of Hematology & …, 2023 - Springer
Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases
N Gangat, P Guglielmelli, N Szuber… - American journal of …, 2021 - Wiley Online Library
Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an
effective treatment regimen for acute myeloid leukemia, in both de novo and …
effective treatment regimen for acute myeloid leukemia, in both de novo and …
[HTML][HTML] Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax+ …
Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …